Wegovy® mimics the action of the natural hormone GLP-1, which regulates appetite and food intake. By acting on specific brain receptors, it helps you feel fuller for longer, reduces hunger, and decreases food cravings. This makes it easier to follow a calorie-controlled diet and maintain weight loss.

Clinically proven weight loss – on average, participants lost around 15% of body weight in clinical trials over 68 weeks when combined with diet and exercise.
Sustained results – benefits maintained for up to two years in long-term studies.
Heart health protection – a 20% reduction in the risk of heart attack, stroke, or cardiovascular death in high-risk adults, as shown in the select trial.
Improved cardiometabolic health markers, including lower blood pressure, reduced waist circumference, and improved cholesterol profiles.

Starting dose: 0.25 mg once weekly for 4 weeks.
Gradual dose increase every 4 weeks (0.5 mg → 1.0 mg → 1.7 mg) until reaching the maintenance dose of 2.4 mg once weekly.
Delivered via the Wegovy® FlexTouch® pre-filled pen for self-injection into the abdomen, thigh, or upper arm.
Pens are stored refrigerated before opening and can be kept below 30°C for up to 6 weeks after first use.

Wegovy is not suitable for:

People under 12 years of age
Pregnant or breastfeeding women
Anyone allergic to semaglutide or the listed ingredients
People using other GLP-1 receptor agonist medications

Possible Side Effects
Common side effects include nausea, vomiting, diarrhoea, constipation, and stomach pain, especially during dose escalation. These often lessen over time. Serious but rare side effects can include pancreatitis, gallstones, severe allergic reactions, or bowel obstruction. Always discuss potential risks with your prescriber.

Why Choose Wegovy® from Shape8
Private prescription service with full eligibility screening
Fast, discreet UK delivery
Ongoing medical support to help you achieve and maintain results
Guidance on healthy eating and activity plans tailored to your needs

Common side effects include nausea, vomiting, diarrhoea, constipation, and stomach pain, especially during dose escalation. These often lessen over time. Serious but rare side effects can include pancreatitis, gallstones, severe allergic reactions, or bowel obstruction. Always discuss potential risks with your prescriber.

Wegovy® works gradually, helping you achieve sustainable results rather than rapid, short-term loss. In clinical trials, patients lost on average around 15% of their starting body weight over 68 weeks when combined with a healthy diet and regular physical activity. Many people begin noticing changes in appetite and early weight loss within the first month, with steady progress as the weeks go by.

Your Wegovy® treatment starts at a low dose to help your body adjust, with gradual increases every four weeks until you reach the maintenance dose.

Weeks 1–4: 0.25 mg once weekly
Weeks 5–8: 0.5 mg once weekly
Weeks 9–12: 1.0 mg once weekly
Weeks 13–16: 1.7 mg once weekly
Week 17 onwards: 2.4 mg once weekly (maintenance dose)
This schedule is a general guide. Your exact progression will depend on your response to treatment, any side effects, and your prescriber’s clinical judgement. Your clinician may adjust, delay, or reduce your dose if needed to ensure safe and comfortable progress.

Your Wegovy® treatment starts at a low dose to help your body adjust, with gradual increases every four weeks until you reach the maintenance dose.

Weeks 1–4: 0.25 mg once weekly
Weeks 5–8: 0.5 mg once weekly
Weeks 9–12: 1.0 mg once weekly
Weeks 13–16: 1.7 mg once weekly
Week 17 onwards: 2.4 mg once weekly (maintenance dose)
This schedule is a general guide. Your exact progression will depend on your response to treatment, any side effects, and your prescriber’s clinical judgement. Your clinician may adjust, delay, or reduce your dose if needed to ensure safe and comfortable progress.

• 1 pre-filled Wegovy® FlexTouch® pen (containing four weekly doses)
• 4 disposable needles
• Patient Information Leaflet with step-by-step instructions